Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
- PMID: 27378194
- DOI: 10.1016/j.critrevonc.2016.06.006
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Abstract
Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK] activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin [mTOR] inhibition. This drug leads to activation of the cellular energy-sensing liver kinase B1 [LKB1]/AMPK pathway. LKB1 is implicated as a tumor suppressor gene in molecular pathogenesis of different malignancies. AMPK is a serine/threonine protein kinase that acts as an ultra-sensitive cellular energy sensor maintaining the energy balance within the cell. AMPK activation inhibits mRNA translation and proliferation in cancer cells via down-regulation of PI3K/Akt/mTOR pathway. Moreover, metformin decreases the production of insulin, insulin-like growth factor, inflammatory cytokines and vascular endothelial growth factor, and therefore it exerts anti-mitotic, anti-inflammatory and anti-angiogenetic effects. Recent in vitro and experimental data suggest that metformin electively targets cancer stem cells, and acts together with chemotherapy to block tumor growth in different cancers. Several epidemiological studies and meta-analysis have shown that metformin use is associated with decreased cancer risk and/or reduced cancer mortality for different malignancies. The present review analyzes the recent biological and clinical data suggesting a possible growth-static effect of metformin also in gynecological cancers. The large majority of available clinical data on the anti-cancer potential of metformin are based on observational studies. Therefore long-term phase II-III clinical trials are strongly warranted to further investigate metformin activity in gynecological cancers.
Keywords: AMP-activated protein kinase [AMPK]; Breast cancer; Chemoprevention; Diabetes; Endometrial cancer; Insulin; Insulin-like growth factor [IGF]; Mammalian target of rapamycin [mTOR]; Metformin; Ovarian cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Metformin: its emerging role in oncology.Hormones (Athens). 2011 Jan-Mar;10(1):5-15. doi: 10.14310/horm.2002.1288. Hormones (Athens). 2011. PMID: 21349801 Review.
-
LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.Int J Gynecol Cancer. 2012 Jan;22(1):15-22. doi: 10.1097/IGC.0b013e3182322834. Int J Gynecol Cancer. 2012. PMID: 22080879
-
Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.Med Hypotheses. 2020 Jan;134:109420. doi: 10.1016/j.mehy.2019.109420. Epub 2019 Oct 3. Med Hypotheses. 2020. PMID: 31634770
-
Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.Int J Gynecol Cancer. 2016 Nov;26(9):1667-1672. doi: 10.1097/IGC.0000000000000818. Int J Gynecol Cancer. 2016. PMID: 27654259 Clinical Trial.
-
Metformin and cancer.Rev Diabet Stud. 2013 Winter;10(4):228-35. doi: 10.1900/RDS.2013.10.228. Epub 2014 Feb 10. Rev Diabet Stud. 2013. PMID: 24841876 Free PMC article. Review.
Cited by
-
Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.Med Sci Monit. 2018 Sep 1;24:6093-6101. doi: 10.12659/MSM.909745. Med Sci Monit. 2018. Retraction in: Med Sci Monit. 2021 Mar 25;27:e932331. doi: 10.12659/MSM.932331. PMID: 30171812 Free PMC article. Retracted.
-
Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.Am J Cancer Res. 2019 Oct 1;9(10):2170-2193. eCollection 2019. Am J Cancer Res. 2019. PMID: 31720081 Free PMC article.
-
Phenformin as an Anticancer Agent: Challenges and Prospects.Int J Mol Sci. 2019 Jul 5;20(13):3316. doi: 10.3390/ijms20133316. Int J Mol Sci. 2019. PMID: 31284513 Free PMC article. Review.
-
The effects of metformin monotherapy and combination of metformin and glibenclamide therapy on the expression of RAGE, Sirt1, and Nrf2 genes in peripheral blood mononuclear cells of type 2 diabetic patients.J Diabetes Metab Disord. 2022 Feb 10;21(1):369-377. doi: 10.1007/s40200-022-00984-7. eCollection 2022 Jun. J Diabetes Metab Disord. 2022. PMID: 35673478 Free PMC article.
-
Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women's Health Initiative.J Acad Nutr Diet. 2018 Apr;118(4):617-626. doi: 10.1016/j.jand.2017.06.010. Epub 2017 Aug 17. J Acad Nutr Diet. 2018. PMID: 28826845 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
